• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

儿科蒽环类药物诱导的心脏毒性：机制、药物基因组学和多能干细胞建模。

Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling.

机构信息

Murdoch Childrens Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.

Department of Paediatrics, The Royal Children's Hospital, The University of Melbourne, Parkville, Victoria, Australia.

出版信息

Clin Pharmacol Ther. 2019 Mar;105(3):614-624. doi: 10.1002/cpt.1311. Epub 2019 Jan 11.

DOI:10.1002/cpt.1311
PMID:30460992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6590110/
Abstract

Anthracycline-induced cardiotoxicity (ACT) is a severe adverse drug reaction for a subset of children treated with anthracyclines as part of chemotherapy protocols. The identification of genetic markers associated with increased ACT susceptibility has clinical significance toward improving patient care and our understanding of the molecular mechanisms involved in ACT. Human-induced pluripotent stem cell-derived cardiomyocytes represent a novel approach to determine the pharmacogenomics of ACT and guide the development of genetic screening tests.

摘要

蒽环类药物诱导的心脏毒性（ACT）是接受蒽环类药物化疗方案治疗的一部分儿童的一种严重药物不良反应。确定与增加 ACT 易感性相关的遗传标志物对于改善患者护理和我们对 ACT 相关分子机制的理解具有临床意义。人诱导多能干细胞衍生的心肌细胞代表了一种确定 ACT 的药物基因组学并指导遗传筛选测试开发的新方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbdd/6590110/8811598b789d/CPT-105-614-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbdd/6590110/7d583021ea8f/CPT-105-614-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbdd/6590110/30b1f0f717dc/CPT-105-614-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbdd/6590110/ff456a5684fe/CPT-105-614-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbdd/6590110/8811598b789d/CPT-105-614-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbdd/6590110/7d583021ea8f/CPT-105-614-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbdd/6590110/30b1f0f717dc/CPT-105-614-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbdd/6590110/ff456a5684fe/CPT-105-614-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbdd/6590110/8811598b789d/CPT-105-614-g004.jpg

相似文献

1
Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling.儿科蒽环类药物诱导的心脏毒性：机制、药物基因组学和多能干细胞建模。
Clin Pharmacol Ther. 2019 Mar;105(3):614-624. doi: 10.1002/cpt.1311. Epub 2019 Jan 11.
2
Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.人诱导多能干细胞衍生心肌细胞中蒽环类药物诱导的心脏毒性的基因组生物标志物鉴定：一种用于安全性评估的体外重复暴露毒性方法。
Arch Toxicol. 2016 Nov;90(11):2763-2777. doi: 10.1007/s00204-015-1623-5. Epub 2015 Nov 4.
3
Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).蒽环类药物诱导的心脏毒性：人诱导多能干细胞衍生心肌细胞（hiPSC-CMs）获得的分子见解。
AAPS J. 2021 Mar 14;23(2):44. doi: 10.1208/s12248-021-00576-y.
4
Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.利用 hiPSC 阐明蒽环类抗生素诱导的心脏毒性的基因组易感性。
Pharmacogenomics. 2021 Jan;22(1):41-54. doi: 10.2217/pgs-2020-0104. Epub 2021 Jan 15.
5
Preventing Anthracycline-Induced Cardiotoxicity Using Functional Genomics and Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.利用功能基因组学和人诱导多能干细胞衍生的心肌细胞预防蒽环类药物诱导的心脏毒性
Circulation. 2022 Jan 25;145(4):295-298. doi: 10.1161/CIRCULATIONAHA.121.058128. Epub 2022 Jan 24.
6
Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.利用源自人诱导多能干细胞的三维心脏组织开发体外药物诱导的心脏毒性检测方法。
Tissue Eng Part C Methods. 2018 Jan;24(1):56-67. doi: 10.1089/ten.TEC.2017.0247. Epub 2017 Nov 17.
7
Characterization of the molecular mechanisms underlying azithromycin-induced cardiotoxicity using human-induced pluripotent stem cell-derived cardiomyocytes.利用人诱导多能干细胞衍生的心肌细胞表征阿奇霉素诱导心脏毒性的分子机制
Clin Transl Med. 2021 Sep;11(9):e549. doi: 10.1002/ctm2.549.
8
Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.循环微RNA：接受蒽环类化疗的儿童和青年人心脏毒性的潜在标志物
J Am Heart Assoc. 2017 Apr 4;6(4):e004653. doi: 10.1161/JAHA.116.004653.
9
Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.蒽环类药物诱导的儿童尤文肉瘤心脏毒性：一项纵向研究。
Pediatr Blood Cancer. 2013 May;60(5):842-8. doi: 10.1002/pbc.24404. Epub 2013 Feb 4.
10
Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity.蒽环类药物诱导的心脏毒性的临床和临床前性别相关差异的证据。
Biol Sex Differ. 2018 Aug 29;9(1):38. doi: 10.1186/s13293-018-0198-2.

引用本文的文献

1
Clinical and cost-effectiveness of pharmacogenomic testing for anthracycline-induced cardiotoxicity in childhood cancer: a systematic review and meta-analysis.儿童癌症中蒽环类药物所致心脏毒性的药物基因组学检测的临床及成本效益：一项系统评价和荟萃分析
Front Pharmacol. 2025 Jul 16;16:1568320. doi: 10.3389/fphar.2025.1568320. eCollection 2025.
2
Time course of hypertension and myocardial dysfunction following anthracycline chemotherapy in pediatric patients.小儿患者蒽环类化疗后高血压和心肌功能障碍的时间进程。
Int J Cardiol Heart Vasc. 2024 May 31;53:101436. doi: 10.1016/j.ijcha.2024.101436. eCollection 2024 Aug.
3

本文引用的文献

1
RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin.诱导多能干细胞衍生心肌细胞的 RNA 序列分析显示，阿霉素反应时 DNA 损伤和细胞周期基因的表达发生改变。
Toxicol Appl Pharmacol. 2018 Oct 1;356:44-53. doi: 10.1016/j.taap.2018.07.020. Epub 2018 Jul 19.
2
Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes.通过诱导心肌细胞中的分子反应 QTL 图谱确定蒽环类药物心脏毒性的遗传基础。
Elife. 2018 May 8;7:e33480. doi: 10.7554/eLife.33480.
3
Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk.
Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes.
多柔比星诱导的心脏毒性相关基因的功能验证
JACC CardioOncol. 2024 Jan 23;6(1):38-50. doi: 10.1016/j.jaccao.2023.11.008. eCollection 2024 Feb.
4
Anticancer therapy-induced adverse drug reactions in children and preventive and control measures.儿童抗癌治疗引起的药物不良反应及防治措施
Front Pharmacol. 2024 Feb 15;15:1329220. doi: 10.3389/fphar.2024.1329220. eCollection 2024.
5
Correlation of Speckle-Tracking Echocardiography with Traditional Biomarkers in Predicting Cardiotoxicity among Pediatric Hemato-Oncology Patients: A Comprehensive Evaluation of Anthracycline Dosages and Treatment Protocols.斑点追踪超声心动图与传统生物标志物在预测儿科血液肿瘤患者心脏毒性中的相关性：对蒽环类药物剂量和治疗方案的综合评估
Children (Basel). 2023 Aug 30;10(9):1479. doi: 10.3390/children10091479.
6
Zymosan A Improved Doxorubicin-Induced Ventricular Remodeling by Evoking Heightened Cardiac Inflammatory Responses and Healing in Mice.酵母聚糖 A 通过诱发强烈的心脏炎症反应和修复改善了多柔比星诱导的心室重构。
J Am Heart Assoc. 2023 Sep 19;12(18):e030200. doi: 10.1161/JAHA.123.030200. Epub 2023 Sep 13.
7
Modeling Cardiotoxicity in Pediatric Oncology Patients Using Patient-Specific iPSC-Derived Cardiomyocytes Reveals Downregulation of Cardioprotective microRNAs.使用患者特异性诱导多能干细胞衍生的心肌细胞对儿科肿瘤患者的心脏毒性进行建模，揭示了心脏保护微小RNA的下调。
Antioxidants (Basel). 2023 Jul 3;12(7):1378. doi: 10.3390/antiox12071378.
8
Molecular mechanisms of anthracycline induced cardiotoxicity: Zebrafish come into play.蒽环类药物诱导心脏毒性的分子机制：斑马鱼发挥作用。
Front Cardiovasc Med. 2023 Mar 10;10:1080299. doi: 10.3389/fcvm.2023.1080299. eCollection 2023.
9
Diquat Herbicide Organophosphate Poisoning and Multi-Organ Failure: A Case Report.敌草快除草剂与有机磷中毒及多器官功能衰竭：一例报告
Cureus. 2022 Jul 25;14(7):e27241. doi: 10.7759/cureus.27241. eCollection 2022 Jul.
10
Disclosing an In-Frame Deletion of the Titin Gene as the Possible Predisposing Factor of Anthracycline-Induced Cardiomyopathy: A Case Report.揭示肌联蛋白基因框内缺失可能是蒽环类药物诱导性心肌病的致病因素：病例报告。
Int J Mol Sci. 2022 Aug 17;23(16):9261. doi: 10.3390/ijms23169261.
化疗相关性心脏功能障碍：遗传变异个体风险调节的系统评价。
Circ Genom Precis Med. 2018 Jan;11(1):e001753. doi: 10.1161/CIRCGEN.117.001753.
4
Expression Profiling of Human Pluripotent Stem Cell-Derived Cardiomyocytes Exposed to Doxorubicin-Integration and Visualization of Multi-Omics Data.多组学数据的整合与可视化分析：多柔比星处理后人多能干细胞源性心肌细胞的表达谱分析
Toxicol Sci. 2018 May 1;163(1):182-195. doi: 10.1093/toxsci/kfy012.
5
Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer.外显子组芯片分析确定GPR35是儿童癌症中蒽环类药物诱导的心脏毒性的一个新的易感基因。
Pharmacogenet Genomics. 2017 Dec;27(12):445-453. doi: 10.1097/FPC.0000000000000309.
6
Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors.高血压易感性基因座与长期儿童癌症幸存者蒽环类药物相关心脏毒性相关。
Sci Rep. 2017 Aug 29;7(1):9698. doi: 10.1038/s41598-017-09517-2.
7
Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity.赢得战役，输掉战争：癌症治疗相关心血管毒性的机制和形态学。
Cardiovasc Pathol. 2017 Sep-Oct;30:55-63. doi: 10.1016/j.carpath.2017.06.009. Epub 2017 Jun 30.
8
Genetic determinants of anthracycline cardiotoxicity - ready for the clinic?蒽环类药物心脏毒性的遗传决定因素——准备好应用于临床了吗？
Br J Clin Pharmacol. 2017 May;83(5):1141-1142. doi: 10.1111/bcp.13195. Epub 2017 Jan 24.
9
Cancer treatment and survivorship statistics, 2016.癌症治疗和生存统计，2016 年。
CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.
10
Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.关于基因检测以降低蒽环类药物所致心脏毒性发生率的建议。
Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30.